Tandem Diabetes Care (TNDM) Cash from Operations Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn | 122.43% |
| 10 | Tandem Diabetes Care | 1.13 Bn | 563.08 Mn | 136.79 Mn | 160.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.48% |
| Dec 31, 2025 | -8.66% |
| Sep 30, 2025 | -69.14% |
| Jun 30, 2025 | -80.02% |
| Mar 31, 2025 | -128.59% |
| Dec 31, 2024 | 248.52% |
| Sep 30, 2024 | 48,589.09% |
| Jun 30, 2024 | 16.57% |
| Mar 31, 2024 | 56.37% |
| Dec 31, 2023 | -223.99% |
| Sep 30, 2023 | -99.77% |
| Jun 30, 2023 | -191.62% |
| Mar 31, 2023 | -232.80% |
| Dec 31, 2022 | -70.36% |
| Sep 30, 2022 | -29.88% |
| Jun 30, 2022 | -76.12% |
| Mar 31, 2022 | -51.89% |
| Dec 31, 2021 | 28.86% |
| Sep 30, 2021 | 134.44% |
| Jun 30, 2021 | 86.43% |